These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 267298)

  • 21. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract]   [Full Text] [Related]  

  • 22. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rhesus serological status of hemophilia patients].
    Mikhaĭlova AA; Klimov AA
    Probl Gematol Pereliv Krovi; 1982 Apr; 27(4):35-7. PubMed ID: 6808499
    [No Abstract]   [Full Text] [Related]  

  • 24. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
    Klukowska A; Zieleniewska B
    Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytotoxic antibodies in pregnancy].
    Fagiolo U; Nardelli GB; Pasini C; Tami P
    Riv Ital Ginecol; 1976; 57(1):21-36. PubMed ID: 1028134
    [No Abstract]   [Full Text] [Related]  

  • 26. Hemolysis caused by factor VIII concentrates.
    Orringer EP; Koury MJ; Blatt PM; Roberts HR
    Arch Intern Med; 1976 Sep; 136(9):1018-20. PubMed ID: 962445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA.
    Melbye M; Froebel KS; Madhok R; Biggar RJ; Sarin PS; Stenbjerg S; Lowe GD; Forbes CD; Goedert JJ; Gallo RC
    Lancet; 1984 Dec; 2(8417-8418):1444-6. PubMed ID: 6151053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study on the levels of anti-A, anti-B isoagglutinin titer in various kinds of concentrates for hemophilia treatment--with special regard to the manufacturing process of factor VIII concentrate].
    Tomita Y; Inagaki M; Taki M; Miura T; Saito N; Sato R; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Feb; 26(2):166-70. PubMed ID: 3927035
    [No Abstract]   [Full Text] [Related]  

  • 30. Red Cell Alloimmunization In Multitransfused Thalassaemia Major Patients.
    Moeen S; Farooq N; Irshad R; Ashfaq M; Farooq U; Idris M
    J Ayub Med Coll Abbottabad; 2018; 30(1):81-84. PubMed ID: 29504337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Red blood cell alloimmunization complicating plasma transfusion.
    Ching EP; Poon MC; Neurath D; Ruether BA
    Am J Clin Pathol; 1991 Aug; 96(2):201-2. PubMed ID: 1907429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to part of the Rho antigen complex occurring in two women with Rho variants.
    Zaino EC; Applewhaite F
    Transfusion; 1975; 15(3):256-9. PubMed ID: 805484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.
    Ehrenforth S; Kreuz W; Scharrer I; Linde R; Funk M; Güngör T; Krackhardt B; Kornhuber B
    Lancet; 1992 Mar; 339(8793):594-8. PubMed ID: 1347102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of Rh anti-E and anti-c production among Japanese after blood transfusion.
    Komatsu F
    Bull Tokyo Med Dent Univ; 1988 Sep; 35(3):75-9. PubMed ID: 3148374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Isoimmune antibody formation after blood transfusions].
    Schricker KT; Kluge R
    Prakt Anaesth; 1976 Oct; 11(5):303-9. PubMed ID: 981140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hemolysins and isoagglutinins in substitute preparations containing factor VIII].
    Göbel U; Ranke M
    Blut; 1972 Jun; 24(6):365-71. PubMed ID: 5057724
    [No Abstract]   [Full Text] [Related]  

  • 38. The high risk of chronic liver disease in multitransfused juvenile hemophiliac patients.
    Spero JA; Lewis JH; Fisher SE; Hasiba U; Van Thiel DH
    J Pediatr; 1979 Jun; 94(6):875-8. PubMed ID: 448527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoimmunization and hemolytic transfusion reaction due to anti-c and anti-Jk combination.
    Kanra T; Pirnar A
    Turk J Pediatr; 1977; 19(1-2):31-8. PubMed ID: 106498
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
    Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
    Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.